Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein.

MLA

Raadsen, Matthijs P., et al. “Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein.” Journal of Infectious Diseases, vol. 228, no. 5, Sept. 2023, pp. 586–90. EBSCOhost, https://doi.org/10.1093/infdis/jiad052.

APA

Raadsen, M. P., Dahlke, C., Fathi, A., Lamers, M. M., van den Doel, P., Zaeck, L. M., Royen, M. E. van, Bruin, E. de, Sikkema, R., Koopmans, M., Gorp, E. C. M. van, Sutter, G., Vries, R. D. de, Addo, M. M., & Haagmans, B. L. (2023). Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein. Journal of Infectious Diseases, 228(5), 586–590. https://doi.org/10.1093/infdis/jiad052

Chicago

Raadsen, Matthijs P, Christine Dahlke, Anahita Fathi, Mart M Lamers, Petra van den Doel, Luca M Zaeck, Martin E van Royen, et al. 2023. “Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein.” Journal of Infectious Diseases 228 (5): 586–90. doi:10.1093/infdis/jiad052.